1.VU T C, NUTT J G, HOLFORD N H G. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson’s disease[J]. Br J Clin Pharmacol, 2012, 74(2):284-295.
2.KEHAGIA A A, BARKER R A, ROBBINS T W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease[J]. Lancet Neurol, 2010, 9(12):1200-1213.
3.LEVY G, TANG M X, LOUIS E D, et al. The association of incident dementia with mortality in PD[J]. Neurology, 2002, 59(11):1708-1713.
4.BENKE T, HOHENSTEIN C, POEWE W, et al. Repetitive speech Phenomena in parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 2000, 69(3):319-324.
5.KEHAGIA A A, BARKER R A, ROBBINS T W. Cognitive impairment in Parkinson’s disease: The dual syndrome hypothesis[J]. Neurodegener Dis, 2013, 11(2):79-92.
6.MIJUNG Y, SORA A, JU-YOUNG O, et al. Atopic dermatitis induces anxiety-and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2020, 98(2):109818.
7.ALEXANDER G E, DELONG M R, STRICK P L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex[J]. Annu Rev Neurosci, 1986, 9:357-381.
8.SAWAMOTO N, HONDA M, HANAKAWA T, et al. Cognitive slowing in parkinson disease is accompanied by hypofunctioning of the striatum[J]. Neurology, 2007, 68(13):1062-1068.
9.李兵, 李彥, 聶坤, 等. 膽鹼能系統功能紊亂與帕金森病輕度認知功能障礙研究進展[J]. 中華老年心腦血管病雜誌, 2017, 19(6):659-661.
10.DEL TREDICI K, BRAAK H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia[J]. J Neurol Neurosurg Psychiatry, 2013, 84(7):774-783.
11.NEWMAN L A, DARLING J, MC GAUGHY J. Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex[J]. Psychopharmacology (Berl), 2008, 200(1):39-50.